Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | F13A1 | P00488 | 4/20 | 0.35 |
| ▸ | TGM2 | P21980 | 4/20 | 0.35 |
| ▸ | TGM1 | P22735 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494732 | 0.84 | USP2 (0.43) | USP2SMN1; SMN2EPHX2EPHX1F13A1 | |
| SCHEMBL19960620 | 0.83 | USP2 (0.42) | USP2SMN1; SMN2CNR2EPHX2EPHX1 | |
| SCHEMBL30289446 | 0.83 | USP2 (0.42) | USP2SMN1; SMN2EPHX2EPHX1F13A1 | |
| SCHEMBL16083938 | 0.80 | USP2 (0.39) | USP2SMN1; SMN2EPHX2EPHX1F13A1 | |
| SCHEMBL3493297 | 0.80 | JAK2 (0.41) | USP2SMN1; SMN2ALDH1A1 | |
| SCHEMBL2604310 | 0.79 | PKM (0.46) | USP2SMN1; SMN2EPHX2EPHX1F13A1 | |
| SCHEMBL31068605 | 0.79 | USP2 (0.38) | USP2SMN1; SMN2TSHRALOX15ATM | |
| SCHEMBL7905900 | 0.79 | ALDH1A1 (0.39) | TSHRALDH1A1 | |
| SCHEMBL5240170 | 0.79 | ALDH1A1 (0.40) | USP2SMN1; SMN2CNR2EPHX2EPHX1 | |
| SCHEMBL1224512 | 0.78 | USP2 (0.45) | USP2SMN1; SMN2EPHX2EPHX1F13A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2123652-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | ACACA, ACAT1, CPT1B | USP2 3819/4885SMN1; SMN2 889/4885CNR2 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.